• 1
    Nakamura N, Momoi Y, Watari T, Yoshino T, Tsujimoto H and Hasegawa A. Plasma thymidine kinase activity in dogs with lymphoma and leukemia. The Journal of Veterinary Medical Science 1997; 59: 957960.
  • 2
    von Euler H, Einarsson R, Olsson U, Lagerstedt AS and Eriksson S. Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease. Journal of Veterinary Internal Medicine 2004; 18: 696702.
  • 3
    Madewell BR. Editorial: serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma. Journal of Veterinary Internal Medicine 2004; 18: 595596.
  • 4
    von Euler H, Ohrvik AB and Eriksson SK. A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs. Research in Veterinary Science 2006; 80: 1724.
  • 5
    von Euler H, Rivera P, Aronsson AC, Bengtsson C, Hansson LO and Eriksson SK. Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity - evaluation of a new, fully automated non-radiometric assay. International Journal of Oncology 2009; 34: 505510.
  • 6
    Thamm D, Kamstock DA, Sharp CR, Johnson SI, Mazzaferro E, Herold LV, Barnes SM, Winkler K and Selting KA. Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma. Veterinary and Comparative Oncology 2012; 10: 292302.
  • 7
    Yamamoto S, Shida T, Miyaji H, Santsuka H, Fujise H, Mukawa K, Furukawa E, Nagae T and Naiki M. Changes in serum C-reactive protein levels in dogs with various disorders and surgical traumas. Veterinary Research Communications 1993; 17: 8593.
  • 8
    Yamamoto S, Shida T, Okimura T, Otabe K, Honda M, Ashida Y, Furukawa E, Sarikaputi M and Naiki M. Determination of C-reactive protein in serum and plasma from healthy dogs and dogs with pneumonia by ELISA and slide reversed passive latex agglutination test. The Veterinary Quarterly 1994; 16: 7477.
  • 9
    Ceron JJ, Eckersall PD and Martynez-Subiela S. Acute phase proteins in dogs and cats: current knowledge and future prospectives. Veterinary Clinical Pathology 2005; 34: 8599.
  • 10
    Nielsen L, Toft N, Eckersall PD, Mellor DJ and Morris JS. Serum C-reactive protein concentration as a indicator of remission status in dogs with multicentric lymphoma [abstract]. Journal of Veterinary Internal Medicine 2007; 21: 12311236.
  • 11
    Mischke R, Waterston M and Eckersall PD. Changes in C-reactive protein and haptoglobin in dogs with lymphatic neoplasia. Veterinary Journal 2007; 188: 192.
  • 12
    Nakamura M, Takahashi M, Ohno K, Koshino A, Nakashima K, Setoguchi A, Fujino Y and Tsujimoto H. C-reactive protein concentration in dogs with various diseases. The Journal of Veterinary Medical Science 2008; 70: 127131.
  • 13
    Sheahan D, Bell R, Mellanby RJ, Gow AG, Friend E, Heller J, Bence LM and Eckersall PD. Acute phase protein concentrations in dogs with nasal disease. The Veterinary Record 2010; 167: 895899.
  • 14
    Dabrowski R, Kostro K, Lisiecka U, Szczubiał M and Krakowski L. Usefulness of C-reactive protein, serum amyloid A component, and haptoglobin determinations in bitches with pyometra for monitoring early post-ovariohysterectomy complications. Theriogenology 2009; 72: 471476.
  • 15
    Xu XH, Zhang YM, Shu XH, Shan LH, Wang ZW, Zhou YL, Wen HK, He F, He E and Skog S. Serum thymidine kinase 1 reflects the progression of premalignant and malignant tumors during therapy. Molecular Medicine Reports 2008; 1: 705711.
  • 16
    Chen Y, Ying M, Chen Y, Hu M, Lin Y, Chen D, Li X, Zhang M, Yun X, Zhou J, He E and Skog S. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings. International Journal of Clinical Oncology 2010; 15: 359368.
  • 17
    Elliott JW, Cripps P and Blackwood L. Thymidine kinase assay in canine lymphoma. Veterinary and Comparative Oncology 2011; 11: 113.
  • 18
    Hannigan BM, Barnett YA, Armstrong DBA, McKelvey-Martin VJ and McKenna PG. Thymidine kinases: the enzymes and their clinical usefulness. Cancer Biotherapy 1993; 8: 189197.
  • 19
    Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP and Platz EA. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. International Journal of Cancer 2008; 123: 11331140.
  • 20
    Qian BZ and Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 131: 3951.
  • 21
    Rakoff-Nahoum S. Cancer mechanisms: why cancer and inflammation? The Yale Journal of Biology and Medicine 2006; 79: 123130.
  • 22
    Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646674.
  • 23
    Coussens LM and Werb Z. Inflammation and cancer. Nature 2002; 420: 860867.
  • 24
    Chen CC, Chang TW, Chen FM, Hou MF, Hung SY, Chong IW, Lee SC, Zhou TH and Lin SR. Combination of multiple mRNA markers (PTTG1, survivin, UbcH10 and TK1) in the diagnosis or Taiwanese patients with breast cancer by membrane assay. Oncology 2006; 70: 438446.
  • 25
    Connolly Y, Littler E, Sun N, Chen X, Huang PC, Stacey SN and Arrand JR. Antibodies to Epstein-Barr virus thymidine kinase: a characteristic marker for the serological detection of nasopharyngeal carcinoma. International Journal of Cancer 2001; 91: 692697.
  • 26
    Jasensky JK, Hennies M, Kohn B, Einspanier R. Development of an Enzyme-linked immunosorbent assay (ELISA) for the measurement of canine C-reactive protein. Poster and abstract, InnLab Conference 2012, Gottingen, Germany, February 2–3, 2012.
  • 27
    Chen ZH, Huang SQ, Wang Y, Yang AZ, Wen J, Xu XH, Chen Y, Chen QB, Wang YH, He E, Zhou J and Skog S. Serological thymidine kinase 1 is a biomarker for early detection of tumours—a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay. Sensors 2011; 11: 1106411080.